New Data on Yescarta's Efficacy in LBCL Presented at ASH 2025 Reveals Safety and Quality of Life Benefits Recent analyses presented at ASH 2025 demonstrate Yescarta's consistent safety and effectiveness for LBCL patients, including quality of life improvements.

New Data on Yescarta's Efficacy in LBCL Presented at ASH 2025 Reveals Safety and Quality of Life Benefits #United_States #Santa_Monica #Kite #Yescarta #LBCL

→ La catégorie la plus importante est celle des maladies #Hématologiques 🩸, qui couvrent des maladies comme le #Lymphome, le #MyélomeMultiple et l’ #Hémophilie

→ l’oncologie est la suivante, dirigée par les #ThérapiesCellulaires #CAR_T 🧬 comme #Kymriah, #Yescarta et #Breyanzi

J&J’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study Analysts at Truist Securities called J&J’s CAR T readout “compelling,” noting that the efficacy figures could position the cell therapy as a formidable competitor to the current standard of care, Gile...

La thérapie #CAR_T 🧬 expérimentale #JNJ_4496 de #JohnsonAndJohnson a déclenché une réponse au traitement chez 100 % des patients atteints d’un #Lymphome 🩸 à grandes cellules B, ce qui pose un défi à la norme de soins actuelle de #Gilead, #Yescarta
#CAR_Tcells
www.biospace.com/drug-develop...

Yescarta (Axicabtagene ciloleucel) | Relatório de avaliação de financiamento público disponível na Infomed Infarmed

Yescarta (Axicabtagene ciloleucel) | Relatório de avaliação de financiamento público disponível na Infomed

➡️ tinyurl.com/ubtf2dhs

#infarmed #yescarta #medicamentos #financiamentopublico

Yescarta (Axicabtagene ciloleucel) | Relatório de avaliação de financiamento público disponível na Infomed Infarmed

Yescarta (Axicabtagene ciloleucel) | Relatório de avaliação de financiamento público disponível na Infomed
Mais informações em: ⤵
swki.me/pqMkvkVv

#infarmed #medicamentos #financiamentopúblico #yescarta